Abstract: A method for transferring data from a database may include receiving, at a database management system, a request to transfer, to a client, at least a portion of data stored at a database coupled with the database management system. The database management system may respond to the request by at least generating an internal table containing at least the portion of the data being transferred to the client. The database management system may further transfer at least the portion of the data to the client by at least sending, to the client, one or more data chunks. Each of the one or more data chunks may include at least a portion of a column of data from the internal table. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: This disclosure relates generally to method and system for securing peer nodes in a blockchain network. The proposed disclosure is a robust model providing secure, scalable and efficient sharding committee reconfiguration technique where blockchain peer nodes organize themselves into each sharding committee among a plurality of sharding committees. The disclosure includes, generating a random number directory by each peer node communicating random numbers to the reference committee through leader node in the blockchain network. The reference committee initiates to reconfigure members of each sharding committee at predefined intervals. Further, a first message packet from each peer node is received by the reference committee based on which a second message packet is generated enabling each peer node of the block chain network to join one of the sharding committee.

Abstract: A hybrid heart valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The hybrid heart valve includes a substantially non-expandable, non-compressible prosthetic valve member having a peripheral sealing ring and an expandable stent frame projecting from an inflow end, thereby enabling attachment to the annulus without sutures. The stent frame may be plastically-expandable and may have a thin fabric layer covering its entirety as well as secondary sealing structures around its periphery to prevent paravalvular leaking. Other sealing solutions include interactive steps at the time of valve implant to establish seals around the stent and especially between the stent and the sealing ring of the valve member.

Abstract: A control device for an electric machine includes a circuit board and a cooling body, which are joined together, wherein a heat-conducting paste is introduced between the circuit board and the cooling body at least for thermally connecting the circuit board to the cooling body. The circuit board and/or the cooling body has at least one recess, wherein the recess is formed in the lateral direction between a region to be protected and the introduced heat-conducting paste in such a way that, when the circuit board and the cooling body are joined, an excess portion of the laterally spreading heat-conducting paste can be received by the recess.

Abstract: System and method for improving recognition of characters. A system for improving recognition of characters is disclosed. The system comprises at least one processor (10), configured to receive an image (1004) of an article (102) comprising characters to be recognized. The system (100) displays characters as recognized on a display screen (1006). Further, the system (100) is configured to receive user feedback comprising correction of an error made by the system (100) in recognizing at least one character and provide a system feedback comprising display of images or textual descriptions of one or more variants (1012, 1014, 1016, 1018, 1020, 1022) of a character, which is incorrectly recognized by the system, which enables the natural person to adapt writing style to enable better quality inputs to the recognition module. The article (102) is a handwritten paper form (102), filled and captured by the natural person.

Abstract: A computing device includes: a tracking assembly including a camera; a data capture module; and a controller connected with the tracking assembly and the data capture module, the controller configured to: control the tracking assembly to track successive poses of the computing device in a first frame of reference; control the data capture module to capture and decode an indicium placed in a facility; obtain, based on the indicium, a position of a point in the facility in a second frame of reference corresponding to the facility; detect, via the camera, features of a marker placed in the facility; determine, based on the detected features, an orientation of the marker in the second frame of reference; and generate, for each pose in the first frame of reference, a corresponding pose in the second frame of reference according to the position of the point and the orientation.

Abstract: Transaction executions/commits in a blockchain network need to be fast, robust and secure and thus calls for minimal latency in transaction commits. In an execute-order-commit blockchain network, latency is high due to smart contracts been executed at every endorsing node of the blockchain network. A method and system for processing transactions in the blockchain network is disclosed. The system discloses a veriblock architecture, which enables processing a transaction request by executing an associated smart contract along with a proof of correctness of execution of smart contract using only one endorser. Further, enables verifying the smart contract by multiple endorsers. The smart contract associated with the proof, referred herein as a vericontract, is executed to generate an output and the proof using one of a) Verifiable Computing (VC) approach, b) a TEE approach and c) a hybrid approach (combination of VC and TEE).

Abstract: A control device for an electric machine includes a circuit board and a cooling body, which are joined together, wherein a heat-conducting paste is introduced between the circuit board and the cooling body at least for thermally connecting the circuit board to the cooling body. The circuit board and/or the cooling body has at least one recess, wherein the recess is formed in the lateral direction between a region to be protected and the introduced heat-conducting paste in such a way that, when the circuit board and the cooling body are joined, an excess portion of the laterally spreading heat-conducting paste can be received by the recess.

Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

Abstract: An apparatus can be provided which can include a laser arrangement which can be configured to provide a laser radiation, and can include an optical cavity. The optical cavity can include a dispersive optical first arrangement which can be configured to receive and disperse at least one first electro-magnetic radiation so as to provide at least one second electro-magnetic radiation. Such cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the at least one second radiation so as to provide at least one third electro-magnetic radiation. The optical cavity can further include a dispersive optical third arrangement which can be configured to receive and disperse at least one third electro-magnetic radiation so as to provide at least one fourth electro-magnetic radiation.

Abstract: Exemplary apparatus can be provided which can include a laser arrangement that is configured to provide a laser radiation, and including an optical cavity. The optical cavity can include a dispersive optical waveguide first arrangement having first and second sides, and which is configured to (i) receive at least one first electro-magnetic radiation at the first side so as to provide at least one second electro-magnetic radiation, and (ii) to receive at least one third electro-magnetic radiation at the second side so as to provide at least one fourth electro-magnetic radiation. The first and second sides are different from one another, and the second and third radiations are related to one another. The optical cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the fourth radiation so as to provide the first electro-magnetic radiation to the first arrangement.

Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).

Abstract: Methods and systems for automated assessment of respiratory cytology specimens. Embodiments disclosed herein relate to oncology, and more particularly to automated assessment of respiratory cytology specimens for adequacy, diagnosis and treatment decisions for lung carcinoma. A method disclosed herein includes predicting an adequacy of the respiratory cytology specimens using Artificial Intelligence (AI)/deep learning models. The method further includes diagnosing and staging the respiratory cytology specimens on predicting that the respiratory cytology specimens are adequate for further processing. The method further includes generating at least one of an adequate report, an inadequate report, and a diagnosis and staging report.

Abstract: The present invention provides an efficient process for the isolation of natural crystallized thymol product derived from crude natural Monarda citriodora (Jammu Monarda) oil useful for incorporation into foods and beverages in amounts due to strong antimicrobial, antibacterial, antioxidant properties as well as for use as a preservative. The recovery of crystallized thymol product obtained is more than 72% from Hexane-Jammu Monarda oil in a ratio 1:1 under specific conditions. A method for preparing natural thymol in crystal form involves providing crude Jammu Monarda oil in a Flask and gradually reducing the temperature of the flask containing Monarda oil:Hexane in a step-wise manner, thereby producing highly pure crystals (?95.5%) within 48 h. The methods disclosed herein are suitable for pharmaceutical GMP.

Abstract: The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of tulathromycin and gallic acid for the treatment of a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection or a disease, disorder or condition arising from a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection.

Abstract: An apparatus has a housing with a fluid inlet in fluid communication with a fluid flow path, and a fluid outlet. The monitor includes a controllable valve and a diverter that accommodates different types of sensors. The housing includes a dry housing interior fluidly isolated from the fluid flow path. The monitor includes a power generator configured to generate a voltage when fluid flows through the fluid flow path and at least one sensor configured to measure at least one characteristic of a fluid flowing through the fluid flow path. The monitor includes a signal generator configured to transmit signals from the power generator and from the at least one sensor to a remote processor. The power generator is configured to power both the at least one sensor and the signal generator in response to fluid flow through the fluid flow path.

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).